Advocacy letters, blogs and OpEds we have written or signed on to on various issues:


GO2 Foundation for Lung Cancer sends a letter to the congressional authors of Cures 2.0; a follow up to the 21st Century Cures Act, first enacted five years ago. GO2 Foundation is urging Congress to build upon legislation and consider the specialized needs of the lung cancer community in Cures 2.0. GO2 Foundation has developed key recommendations that consider improvements in several key areas including; patient valued care delivery, Preventive Services—Early Detection and Treatment for Lung Cancer, precision medicine, clinical trials, telehealth, and financial resources.    (December)

GO2 Foundation for Lung Cancer  sends a letter to the Georgia Department of Health Commissioner in opposition of its current Medicaid waiver.  While the waiver intends to expand coverage to a larger population of Georgia residents, GO2 Foundation is concerned with a proposal to include a monetary surcharge for individuals who have reported smoking in the last year.  GO2 Foundation encourages Georgia to expand Medicaid coverage, but asks to rescind its proposal that will discourage enrollment and adequate access to life-saving care. (December)

GO2 Foundation joins other organizations in providing comments on a proposed decision memo on Next Generation Sequencing (NGS) for Medicare beneficiaries with Advanced Cancer.  CMS is reconsidering a National coverage Decision made last year that intended to expand coverage for genetic testing of the tumor, it gave guidance for Medicare Advantage Contractors to include coverage policy for hereditary risk of cancer, but did not provide any coverage policy for using NGS to test hereditary cancer for early-stage cancer patients.  CMS opened a comment period in response to the new proposed decision.  GO2 Foundation expressed concern that the new policy proposal still lacks clarity for its coverage of hematological malignancies and requests that clarity in the proposal be made to ensure Medicare beneficiaries with hematological diseases have access to tests using NGS technology. (December)

GO2 Foundation joins other organizations working in science, technology, engineering and medicine in a letter urging congress to complete its FY 2020 Appropriations bill to fulfill funding for research and development programs across multiple agencies.  A complete appropriations package is crucial addressing the nation’s fundamental challenges including chronic and infectious diseases and national security.  (December)

GO2 Foundation extends its support with other organizations in a letter to Senate leadership for the current nominee for Commissioner of the Food and Drug Administration (FDA). As  Chief Medical Executive at The University of Texas MD Anderson Cancer Center; Dr. Stephen Hahn has knowledge as well as firsthand expertise of patient needs and a deep understanding of the breadth of work that needs to be achieved on their behalf.  GO2 Foundation believes that due to his background, he will ensure FDA continues to exceed in science and innovation. (December)

GO2 Foundation and other cancer patient organizations share a collective voice in a letter to Congress urging the passage of a final FY 2020 appropriations package. Specifically, the letter urges that funding for NIH, NCI, and CDC is ensured so that programming, research, and grants continue in the next year. (December)

GO2 Foundation joins other state and national organizations by sending a letter to the California Air Resources Board to strengthen the proposed Advanced Clean Trucks rule to accelerate the widespread adoption of zero-emission vehicles in the medium and heavy duty truck sector and reduce the amount of harmful emissions generated from on-road mobile sources. Go2 Foundation urges the Board to accelerate the rule and deploy hundreds of thousands of zero emission trucks to reach zero emission standards and improve health benefits statewide. (November)

GO2 Foundations joins the American Lung Association on a letter to the California Air Resources Board in support of the “Proposed Vessels At Berth Rule to Address Unacceptable Health Risks” proposal. This proposal extends existing requirements for reducing pollution by expanding the types of ships that will be required to achieve 80 percent emission reductions by 2020. If enacted, the rule has the potential to reduce cancer risks due to at-berth ship pollution by approximately 60 percent near California ports. (November)

GO2 Foundation joins others in a letter to U.S. House and Senate leadership expressing continued support for a long-term reauthorization of Patient-Centered Outcomes Research Institute (PCORI). GO2 Foundation strongly believes in the positive impact PCORI has on our health care system, specifically older adults and the Medicare population. But, GO2 Foundation is concerned about the lack of new funding and the uncertainty surrounding short-term extensions will mean for PCORI’s ability to fund new research and the negative impact it will have on their ability to manage programs and ongoing operations. (November)

GO2 Foundation joins other organizations in a letter to Secretary Azar and a letter to First Lady, Melania Trump, urging the White House Administration to continue with its proposal to ban all non-tobacco-flavored e-cigarettes. As the White House considers exempting mint and menthol flavored e-cigarettes, Go2 Foundation strongly supports a ban of all flavors without any exemption, to avoid cigarette and nicotine additions among our youth. (October)

GO2 Foundation sends a letters of endorsement to Representative Bonamici and Senator Merkley for H.R. 1603 and S.717, the Alan Reinstein Ban Asbestos Now Act of 2019. While studies reveal that exposure to asbestos fibers is linked to an increased risk of lung cancer; full extent of that linkage and awareness of exposure to asbestos is limited. The new legislation aims to address that by requiring a comprehensive study into the risks of legacy asbestos in homes, schools, workplaces, and public places in an effort to ban imports and use of asbestos in the U.S. (October)

GO2 Foundation joins others in a letter to Senate leadership urging the Senate to adopt the funding levels passed by the House for the Department of Defense’s Peer-Reviewed Cancer Research Programs (PRCRP). The house passed a budget of $100 million for PRCRP, which lists 12 cancers eligible for research funding, including lung cancer. Specifically, GO2 Foundation urges the adoption of the house funding as it includes an additional line item that funds lung cancer research with $14 million. (October)

GO2 Foundation joins other organizations in a letter to Senate leadership in support of the proposed $42.1 billion dollars in the Labor-HHS appropriations bill that would allow the NIH to expand its capacity to fund more promising research, provide support for the next generation of researchers, and allow the agency to identify and address other critical needs. While GO2 Foundation is grateful for the bipartisan funding support, GO2 Foundation is calling for Congress to avoid any further delay in finalizing the FY 2020 funding delays so that the NIH can stop operating under a continuing resolution, which leads to budget restraints and uncertainties. (October)

GO2 Foundation joins other organizations in a letter thanking Congressional leadership for passing H.R647, the Palliative Care and Hospice Education and Training Act (PCHETA).  If passed by the Senate and signed by the President, the legislation would provide greater access to palliative care and services to millions of Americans, making a difference for Americans suffering from serious illnesses.  (October)

GO2 Foundation joins others in a letter to Congressional leadership in support of PCORI reauthorization. Specifically, GO2 Foundation applauds Congress for its language on a 10 year reauthorization agreement, its efforts to continue the mandate to conduct comparative clinical effectiveness research (CER). (October)

GO2 Foundation joins other organizations in a letter expressing its comments to Congressional leadership on its initiative to reduce cap out-of-pocket (OOP) costs for Medicare Part D beneficiaries through the introduction of H.R 3, the Lower Drug Costs Now Act of 2019. While in support of reducing out-of-pocket costs for patients, GO2 Foundation’s feedback emphasizes that any policy initiatives but included protections against unintended consequences on the experience of Part D beneficiaries that could result from policy changes included in the legislation. (October)

GO2 Foundation sends a letter to U.S. House and Senate leadership urging Congress to fund the Peer Reviewed Lung Cancer Research Program within the Department of Defense, Congressionally Directed Medical Research Program (CDMRP). It is critical that Congress maintains funding for lung cancer research at 14 million dollars, in which funds many projects that have gone to clinical trials testing new therapies for lung cancer patients. To date, Congress has funded a total 141 million dollars for the lung cancer research program within CDMRP, making it the second largest lung cancer research program outside of the National Cancer Institute.  (October)

GO2 Foundation joins other organizations in a letter urging CMS Administrator, Seema Verma, to not finalize the proposed rule as part of the laboratory date of service policy, in which could affect effective care for patients.  GO2 Foundation believes that finalizing the “Changing the Test Results Requirement” would reinstate access barriers to timely testing that were eliminated with changes to the Date of Service Rule in 2018.  If reinstated, GO2 Foundation worries that patients will face a 14-day waiting period, as reported occurred previously. Prior to the 2018 change, doctors intentionally held onto patient samples for 14 days before sending samples on to the laboratory for testing. (September)

GO2 Foundation joins a letter to express support to President Trump and HHS Secretary Azar for Dr. Ned Sharpless to be nominated and confirmed as the permanent commissioner of the U.S. Food and Drug Administration (FDA). GO2 Foundation believes that it is imperative FDA have a permanent leader as the agency regulates nearly 25 percent of the U.S. economy, including lifesaving therapies for lung cancer. (September)

GO2 Foundation and other members of the Patient Quality of Life Coalition are pleased to announce their support for and participation in the American Academy of Hospice and Palliative Medicine (AAHPM’s) upcoming 2020 State of the Science in Hospice and Palliative Care research symposium. The symposium will continue to encourage support for H.R. 647 and S. 2080, the Palliative Care and Hospice Education and Training Act (PCHETA). (August)

GO2 Foundation and other patient advocacy organizations send a letter to the United States Senate to express support for the Palliative Care and Hospice Education and Training Act (PCHETA). If passed. The legislation would relieve suffering and provide the best possible quality of life for patients and their families. Palliative care can be offered simultaneously with life-prolonging and curative therapies for persons living with serious, complex, and eventually terminal illness and includes hospice care. (July)

GO2 Foundation signs on to a letter sent to Senate Finance Committee leadership urging Congress to improve access to prescription medications in Medicare Part D and safeguard the health of Medicare beneficiaries, through changes to the Prescription Drug Pricing Reduction Act of 2019. (July)

GO2 Foundation joins others in a letter to Senate leadership in support of a policy proposal that would incentivize uptakes of biosimilars through a zero-dollar co-payment for beneficiaries enrolled in Medicare Part B. GO2 Foundation believes that biosimilars hold great promise to lower drug costs and increase patient access to medications, however a lack of uptake threatens the realization of this promise. (July)

GO2 Foundation acknowledges its full support for the use of palliative care for patients at all stages of their disease alongside active treatment. GO2 Foundation stands by the use of palliative care as a measure to achieve better outcomes and improved quality of life for lung cancer patients, survivors, and caregivers. (June)

GO2 Foundation joints other patient organizations in a letter to the Institute for Clinical and Economic Review providing feedback on ICER’s Value Assessment Framework. GO2 Foundation and other organizations do not believe that generating value assessments in a manner that leads to restricted access and discrimination is a necessary tactic or ethical strategy to lowering healthcare costs. The letter provides suggestions for ICER’s framework that aim to lower costs.  (June)

GO2 Foundation joins others in a letter to the Office of Management and Budget in opposition of a proposed rule to adjust the official poverty measure (OPM) or poverty thresholds. If implemented, many would see increased barriers to health care, as fewer Americans would qualify for income assistance programs (June).

GO2 Foundation signed onto a letter urging CMS to extend the comment period for reconsideration of the National Coverage Determination on Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer, pursuant to CAG-00450R.  Currently, the public comment period is only 30 days, concluding on May 29, 2019. The impact CMS’ decision could have on access to NGS-based testing for Medicare beneficiaries and the future of genomic-based testing is of concern, and GO2 Foundation believes an extension will allow all stakeholders to thoroughly assess the reconsideration before providing detailed comments (May).

GO2 Foundation signed onto a letter urging CMS to revise the scope of the National Coverage Decision (NCD) so that it facilitates coverage of Next Generation Sequencing (NGS)-based hereditary/germline testing without influencing existing coverage policies related to the use of NGS-based tumor testing. It also identifies other aspects of the NCD that present additional opportunities for engagement with stakeholders.  (May)

GO2 Foundation  for Lung Cancer, formerly Lung Cancer Alliance, sends letters to the House and Senate with other patient focused organizations expressing its support for the reauthroization of the Patient-Centered Outcomes Research Institute (PCORI). The Institute has the unique advantage to produce healthcare solutions that are both evidence-based and patient-centered which will improve care while addressing spending. PCORI is the only organization funding comparative clinical effectiveness research (CER) studies that compares varying treatment approaches and for which patients. GO2 Foundation believes PCORI will meet today’s challenges to examine quality of care and costs with continued work on its research. (May)

GO2 Foundation  for Lung Cancer, formerly Lung Cancer Alliance, sends a letter to Congressional leadership urging Congress to convene public forums with stakeholders and the Federal Drug Administration (FDA) to discuss ways to revise and develop the Verifying Accurate, Leading-Edge in Vitro CLinical Test Development (VALID) Act, in which will best improve the quality of care to patients while fostering greater innovation in the diagnostic testing community. (May)

GO2 Foundation  for Lung Cancer, formerly Lung Cancer Alliance, and other members of the Friends of Cancer Research Coalition voice opposition to a memorandum from the White House titled, “Guidance on Compliance with the Congressional Review Act” that would alter the guiding process for federal agencies and could harm the health and safety of the public if applied to the Federal Drug Administration (FDA). (April)

Lung Cancer Alliance and other members of the NHLBI Constituency Group sent a letter to Congress urging them to include $41.6 billion for the National Institutes of Health (NIH), including $3.71 billion for the National Heart, Lung, and Blood Institute (NHLBI) in the FY 2020 Labor-HHS-Education Appropriation bill.  Lung Cancer Alliance believes a funding level of this amount would allow the NIH to sustain current activities and invest in promising and critically needed scientific research. (March)

Lung Cancer Alliance sends a letter along with other members of the CDC Coalition to Congress urging Congress to provide at least $7.8 billion for the Centers for Disease Control and Prevention Programs the FY20 Labor, Health and Human Services, and Education Appropriations bill. Lung Cancer Alliance believes that this funding is crucial for all of the activities and programs supported by CDC which are essential to protect the health of all Americans. (March)

Lung Cancer Alliance joins other patient advocacy organizations in a joint letter to the Chairman of the Senate Committee on Heath, Education, Labor and Pensions (HELP), Senator Lamar Alexander providing input on ways to address rising health care costs in the U.S. During an opportunity to provide comments to the U.S. Senate HELP Committee, Lung Cancer Alliance addressed its supports and asks for the committee to consider policies that expand access to palliative care services. (March)

Lung Cancer Alliance sends letter to Congress endorsing HR 913, the Clinical Treatment Act, which would ensure states cover routine care costs of participation in an approved clinical trial for Medicaid beneficiaries with life-threatening conditions. Routine costs include the non-experimental costs of treating a patient participating in a clinical trial. They are standard costs that will be incurred no matter what, and thus has little impact on the overall cost of Medicaid programs and will help patients gain access to critical clinical trials. (February)

Lung Cancer Alliance joins other cancer advocacy organizations by sending a letter to Secretary Azar urging the Center for Medicaid & Medicare Services to not consider or finalize the proposed changes the Medicare Part D six protected classes. Since the initial implementation to the six protected classes, six categories of drugs were identified and required to be covered under Part D plans to ensure all beneficiaries have access to medications needed to treat their conditions. The current proposed changes could lead to barrier to access of necessary drugs and maintain current treatments. (February)

LCA among others have sent a letter to the Center for Medicaid & Medicare Services expressing concerns over recent developments regarding the implementation of the National Coverage Determination (NCD) for Next Generation Sequencing (NGS) for Medicare beneficiaries with advanced cancer. Lung Cancer Alliance believes these developments will restrict patient access to medically necessary and relevant testing of germline mutations in cancer patients as well as impact patient care and outcomes. (February)

LCA and other public interest groups representing cancer researchers, physicians and nurses, patients, survivors and their families join together to express urgency to Congress to work together raise the FY 2020 budget cap. If Congress does not take action, the non-defense discretionary budget cap for FY 2020 will drop by $55 bullion below the FY 2019 level. This change will drastically impact the National Institutes of Health, including the National Cancer Institute, and the Centers for Disease Control and Prevention (CDC) Cancer Prevention and Control Programs. (February)

LCA makes a statement endorsing the Cancer Drug Parity Act of 2019 which will play a role in modernizing insurance benefit designs so that patient out-of-pocket expenses for oral drugs can avoid arbitrary insurance designs that deny patients optimal therapy for their conditions.  With the passage of federal legislation, patients can take medication by pill at similar out-of-pocket costs as medications administered in a doctors office.  LCA believes this is a crucial step in providing affordable access to care for all cancer patients. (January)

LCA makes a statement in support of the Burn Pits Accountability Act of 2019 which ensures that those effected by burn pit toxins are accounted for and benefit from actions designated to address its associated health issues.  LCA also recommends additional research examining the consequences of burn pit exposure and identifying effective tools to treat veterans who have been exposed early that improves health and saves lives. (January)

LCA and other health advocacy organizations send a letter Congressional leaders expressing concern over the impact the partial federal shutdown is having on the operations of the Food and Drug Administration (FDA). As a catalyst for expediting lifesaving therapies to patients, without full funding for the FDA, a continued shutdown puts health and safety of Americans at risk and puts future scientific discovery and innovation in jeopardy. LCA asks that Congress immediately brings back the FDA’s budget to its full capacity. (January)


LCA joins the Friends of Cancer Research Coalition urging the Senate to pass S.3519, the Making Objective Drug Evidence Revisions for New Labeling Act (MODERN Labeling Act). Studies reveal that many prescription drug labels are out of date and if passed, this legislation would require the FDA to update generic drug labels to reflect new scientific information relevant to the drug and its use. This bill will address discrepancies that occur when new scientific information relevant to a drug’s indication is not incorporated into its label and ensure all Americans are provided with appropriate and safe drugs (November)

LCA joins the Research!America community in a letter and the One Voice Against Cancer (OVAC) community in a letter expressing gratitude for Congress’s bipartisan successful efforts to secure an additional $2 billion in funding for the National Institutes of Health, as well as crucial advancements for other important Department of Health and Human Services agencies such as the Centers for Disease Control and Prevention (CDC) and the Agency for Healthcare Research and Quality (AHRQ) as part of H.R. 6157, the Fiscal Year 2019 Labor, Health and Human Services, Education/Defense Appropriations Conference Report.  The successful passage of H.R. 6157 will further insure continued cancer research and cancer control programs. (October)

LCA submits comments to the Center for Medicaid and Medicare Services (CMS) expressing its concerns with the Alabama Medicaid Workforce Initiative 1115 Waiver that would impose work requirements on a population of beneficiaries that already have one of the nation’s strictest income eligibility requirements. This waiver disregards the multitude of reasons that limits one’s ability to comply with additional requirements, puts individuals in a ‘Catch-22’ scenario, and will result in a loss of coverage.  In order for lung cancer patients covered by Medicaid in Alabama to maintain access to necessary care and treatment, LCA believes these work requirements should not be considered. (October)

LCA and American Lung Cancer Foundation (ALCF) write joint comments to the FDA applauding its initiative to utilize real-world data from patient-driven platforms and developing a patient centered committee to consider emerging e-platforms for better patient and consumer engagement.  With careful and thoughtful implementation, real-world data and leveraging e-platforms can help fill gaps in an evolving and advancing health information field to inform and move new technologies and medical devices forward in a safe and effective way.  With additional recommendations to reduce burdens, the two organizations support the use of real-world data and strongly believe it will make substantial improvements to patient care and management. (October)

LCA joins the Part B Access for Seniors and Physicians (ASP) Coalition and sent a letter to Senate and House leaders asking them to urge the Centers for Medicare & Medicaid Services (CMS) to reconsider a proposal to allow Medicare Advantage (MA) plans to implement step therapy to manage Part B drugs.  LCA is concerned that if implemented, doctors could be required to prescribe patients with less effective therapies and drugs ultimately restricting access and decrease therapy choices putting patients’ health at risk and potentially create long-term health care issues. (September)

LCA joins others representing patients, people with disabilities, physicians, and caregivers in a letter urging the President and CEO of CVS to reverse its decision allowing CVS Caremark to deny coverage of drugs that fail to meet a cost-effectiveness threshold. LCA among the others firmly believes that a cost-effectiveness analysis discriminates against the chronically ill, elderly, and people with disabilities as it will deny coverage of drugs for patients if the drugs do not meet a subjective ‘quality-adjusted-life-year’ based threshold. (September)

LCA submits comments to the Center for Medicaid and Medicare Services (CMS) expressing its concerns with the Kentucky HEALTH Medicaid program waiver that would impose work requirements, additional paperwork, lockout periods, and the removal of non-emergency medical transportation coverage; impacting patients’ access to necessary services who are covered by Medicaid in Kentucky. (August)

LCA and the Bonnie J. Addario Lung Cancer Foundation (ALCF) provide comments on the Oregon Health Evidence Review Omission’s (HERC) draft Coverage Guidance Document in which LCA and ALCF express support for the positive clinical utility of Next Generation Sequencing (NGS) testing and its impact on clinical outcomes and decision making. (August)

LCA recently joined 50 leading organizations representing patients and people with disabilities in submitting a letter to the Centers for Medicare and Medicaid Innovation (CMMI) urging the agency to act on their statute’s call for alternative payment models to be evaluated based on patient-centered criteria. (August)

LCA joins others in a letter as a member of the Regulatory Education and Action for Patients (REAP) Coalition, a letter as part of the Patient Advocacy Network, and a letter as a member of the Cancer Support Community that was sent to Health and Human Services Secretary, Alex Azar, in which provides feedback on policies under consideration in the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket costs. (July)

LCA joins the Patient Quality of Life Coalition (PQLC) in a letter to Congress supporting legislative efforts to reduce inappropriate use of opioids and providing rehabilitative assistance for those who have abused, but also urges Congress that any public policy initiative being considered must not  create any barriers to accessing pain management and symptom relief for patients suffering from cancer. (June)

LCA joins others in requesting that Congress (House and Senate) allocate at least $216.5 million for the Centers for Disease Control and Prevention’s (CDC) Office on Smoking and Health (OSH), in which supports critical efforts for tobacco free initiatives. LCA opposes any congressional efforts to eliminate the OSH. (June)

LCA joined Society of Thoracic Surgeons (STS) and American College of Radiology (ACR) in a letter to the United States Preventive Services Task Force (USPSTF), an independent body established by the government to evaluate preventive services, in an effort to shape the next round of USPSTF review for lung cancer screening. The coalition letter encourages USPSTF to evaluate screening from objective information reflecting current studies and real world implementation experience for the benefit of those at high risk. (May)

LCA and other stakeholders sent a joint letter urging the Department of Health and Human Services to ensure Medicare beneficiaries have coverage for lung cancer screening in all eligible sites; which includes Independent Diagnostic Testing Facilities (IDTFs). (May)

LCA joins with others urging the House and Senate to approve the authorized level of funding in the FY19 Budget for the Center for Tobacco Products in order for the FDA to continue its oversight of the manufacturing, distribution, and marketing of tobacco products that will improve U.S. public health. (May)

LCA joins other advocates and industry stakeholders urging Congress to enact legislation to modernize the oversight of clinical laboratory tests, which will increase patient access to innovative drugs while ensuring adequate safety. (May)

LCA and 153 other members of the CDC Coalition sent a letter to the Chairs of the Senate and House Appropriations Subcommittee on Labor, Health and Human Services, Education and Related Agencies urging Congress to provide $8.445 billion for the Centers for Disease Control and Prevention’s programs in the FY 19 Labor, Health and Human Services, Education and Related Agencies Appropriations bill. This bill will continue to fund all of the activities and programs supported by CDC and are essential to protect the health of the American people. (April)

LCA joins cancer groups in a letter encouraging Congress to review other policy options that improve the ability of patients to quickly and safely access both approved and unapproved innovative, lifesaving therapies. (February)


LCA signed on with ACS CAN’s Patient Quality of Life Coalition (PQLC) to offer comments regarding questions relevant to the Food and Drug Administration’s (FDA’s) new Opioid Policy Steering Committee. (December)

LCA signed onto a letter that was sent to HHS Acting Secretary Eric Hargan regarding the media reports of restrictions on the use of certain language in CDC’s FY 2019 budget documents. (December)

Following the Senate’s passage of the tax bill, LCA, the National Organization for Rare Diseases and 162 other advocacy organizations signed onto a letter requesting that Congress preserve the Orphan Drug Tax Credit within the Tax Cuts and Jobs Act Conference Report. The Senate’s version proposes to cut the credit’s value from 50 percent of qualified clinical testing expenses, to 27.5 percent. The House version repeals the credit entirely. (December)

LCA joined the CDC Coalition in letters to the House and Senate Appropriations Committee and Labor-HHS-Ed Appropriations Subcommittee leaders requesting at least $7.8 billion for CDC’s programs in any final FY 2018 funding bill and a restoration of the cuts that were made to several CDC programs in the House and Senate Appropriations Committee-passed bills from earlier this year. (December)

LCA signed onto a letter with One Voice Against Cancer (OVAC) encouraging Congress to reach a bipartisan agreement to lift the budget caps in order to provide the NIH and CDC with greater resources to pursue life-saving advances in cancer research, early detection and prevention. (November)

LCA comments to CMS on CMMI’s new direction to promote patient-centered care and test market-driven reforms that empower beneficiaries as consumers, provide price transparency, increase choices and competition to drive quality, reduce costs, and improve outcomes. (November)

Statement by LCA and 90 other patient organizations in opposition to the House of Representative’s Repeal of the Orphan Drug tax credit. Statement by LCA and 36 patient organizations in opposition to the Senate’s proposed weakening of the Orphan Drug Tax Credit.

LCA sent LCA’s Letter to Anthem Blue Shield & Blue Cross urging them to reconsider its recent policy change in at least nine states to deny coverage of Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) services performed in hospital outpatient departments, which will affect the lung cancer at-risk community. (October)

LCA signed on to DHRC Letter to Thornberry_Policy Letter and its importance to the readiness of the U.S. Armed Services. (October)

LCA joined Friends of Cancer, ACSCAN and NORD in a letter addressing concerns for legislation, S.204, and H.R.878. Together we encourage leaders of the House Committee of Energy and Commerce to consider policy options that help cancer patients access unapproved treatment and therapies safely. (September)

LCA and 13 other patient organizations joined forces to comment in response to the “Laboratory Date of Service Policy” (DOS) in the Centers for Medicare & Medicaid Services (CMS) Hospital Outpatient Prospective Payment System (HOPPS) Proposed Rule for Calendar Year 2018, encouraging the elimination of unnecessary barriers that prevent patients from receiving the best care. (September)

LCA joined other patient advocacy organizations in a letter House and Senate Appropriations leaders to ensure transfer authority between the NCI and the FDA for Moonshot Initiative efforts. (July)

As a founding member of the Deadliest Cancers Coalition, LCA joins a letter to express our concern about the “Better Care Reconciliation Act,” the Senate version of the health bill released on June 22. (June)

LCA sends letter to Majority Leader McConnell and Minority Leader Schumer voicing concerns about the “Better Care Reconciliation Act of 2017” and how it will impact the lung cancer community. (June)

LCA joins Trust for America’s Health by signing on a letter to the Senate opposing the repeal of the Prevention and Public Health Fund within the CDC, Proposed in the Senate’s Better Care Reconciliation Act (H.R. 1628) at the start of FY18. (June)

LCA signs onto letter urging Congress to maintain Medicaid expansion. (June)

Letter urging the HHS to protect patient access and oppose harmful recommendations to Medicare Part B. (June)

LCA supports H.R. 1662, which would make facilities of the Veterans Health Administration (VHA) smoke-free. (May)

Centers for Disease Control and Prevention Coalition requests 7.8 billion in FY18 Appropriations for CDC’s Public Health Programs. (April)

Deadliest Cancer Coalition letter rejecting proposed $5.8 billion cut to NIH/NCI in FY2018 President’s Skinny Budget. (March)

Letter requesting funding in FY18 for the US Environmental Protection Agency (EPA) to fight radon, the second leading cause of lung cancer. (March)

Letter to Administrator Pruitt requesting specific funding in EPA’s FY18 budget to support the Radon Program and the State Indoor Radon Grant (SIRG) Program. (March)

Joint letter with One Voice Against Cancer Coalition to oppose budget cuts and advocate increase for the NIH funding. (March)

Congressional Lung Cancer Caucus officially re-established (March)

Joint letter with American Association of Radon Scientists and Technologists against cuts to EPA radon programs (March)

Partnership for safe medicines letter to Congress on counterfeit medicines (February)

Deadliest Cancers Coalition supporting  NIH funding (February)

Joint letter urging Congress to work together to complete the fiscal year 2017 appropriations process and secure funding for lung cancer within the CDMRP fiscal year 2017 Defense Appropriations Act. (February)

Joint letter with ACS-CAN to Senate and House addressing possible loss of key protections to access to affordable insurance coverage for patients with preexisting health conditions. (February)

OpEd: Putting Patients First (February)

Joint letter with American Lung Association and 18 lung cancer groups on Affordable Care Act (February)

One Voice Against Cancer support letter for 21st Century Cures (January)

Joint letter with ACS-CAN and 31 other national organizations requesting action on LDT oversight (January)


Coalition letter to CMS with comments on new reimbursements for screening (December)

Letter to United States Preventive Services Task Force on tobacco cessation (December)

One Voice Against Cancer Support Letter for 21st Century Cures (November)

Deadliest Cancer Coalition Supporting Moonshot Funding for 2017 (November)

Congressionally Directed Medical Research Program in DOD Support for FY17 (November)

CDC Coalition letter supporting FY17 funding (October)

Coalition Letter to CMS against reimbursement reductions for screening (September)